Pharmacology in Peripheral Arterial Disease: What the Interventional Radiologist Needs to Know

 

 Buy Article Permissions and Reprints

Abstract

Peripheral arterial disease (PAD) is a progressive disease with significant morbidity and mortality. Risk factor control, using diet and lifestyle modification, exercise, and pharmacological methods, improves symptoms and reduces associated cardiovascular events in these patients. Antiplatelet agents and anticoagulants may be used to reduce the incidence of acute events related to thrombosis. The armamentarium available for symptom relief and disease modification is discussed. Novel treatments such as therapeutic angiogenesis are in their evolutionary phase with promising preclinical data.

• References

• 1 Diehm C, Allenberg JR, Pittrow D , et al; German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120 (21) 2053-2061
  CrossrefPubMedGoogle Scholar
• 2 National Institute for Health and Care Excellence. Lower limb peripheral arterial disease: diagnosis and management (CG147) London: National Institute for Health and Care Excellence; 2012. Available at: https://www.nice.org.uk/guidance/cg147 . Accessed June 30, 2014
  PubMedGoogle Scholar
• 3 Tendera M, Aboyans V, Bartelink ML , et al; European Stroke Organisation; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (22) 2851-2906
  CrossrefPubMedGoogle Scholar
• 4 2011 WRITING GROUP MEMBERS; 2005 WRITING COMMITTEE MEMBERS; ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124 (18) 2020-2045
  CrossrefPubMedGoogle Scholar
• 5 Scottish Intercollegiate Guidelines Network. Diagnosis and Management of Peripheral Arterial Disease: A National Clinical Guideline Number 89. Edinburgh: Scottish Intercollegiate Guidelines Network; 2006
  Google Scholar
• 6 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG ; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67
  CrossrefPubMedGoogle Scholar
• 7 Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 2014; 100 (5) 414-423
  CrossrefPubMedGoogle Scholar
• 8 Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease?. Public Health 2013; 127 (5) 435-441
  CrossrefPubMedGoogle Scholar
• 9 Lu L, Mackay DF, Pell JP. Association between level of exposure to secondhand smoke and peripheral arterial disease: cross-sectional study of 5,686 never smokers. Atherosclerosis 2013; 229 (2) 273-276
  CrossrefPubMedGoogle Scholar
• 10 Lu L, Mackay DF, Pell JP. Secondhand smoke exposure and intermittent claudication: a Scotland-wide study of 4231 non-smokers. Heart 2013; 99 (18) 1342-1345
  CrossrefPubMedGoogle Scholar
• 11 Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42 (1) 67-74
  CrossrefPubMedGoogle Scholar
• 12 Myers K, Hajek P, Hinds C, McRobbie H. Stopping smoking shortly before surgery and postoperative complications: a systematic review and meta-analysis. Arch Intern Med 2011; 171 (11) 983-989
  PubMedGoogle Scholar
• 13 National Institute for Health and Care Excellence. Smoking cessation services (PH10). London: National Institute for Health and Care Excellence; 2013. . Available at: http://www.nice.org.uk/guidance/ph102013 . Accessed June 30, 2014
  Google Scholar
• 14 Carson KV, Brinn MP, Robertson TA , et al. Current and emerging pharmacotherapeutic options for smoking cessation. Subst Abus 2013; 7: 85-105
  PubMedGoogle Scholar
• 15 Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014; 129 (1) 28-41
  CrossrefPubMedGoogle Scholar
• 16 Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96 (1) 44-49
  CrossrefPubMedGoogle Scholar
• 17 Feringa HH, Karagiannis SE, van Waning VH , et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007; 45 (5) 936-943
  CrossrefPubMedGoogle Scholar
• 18 Stalenhoef AF. The benefit of statins in non-cardiac vascular surgery patients. J Vasc Surg 2009; 49 (1) 260-265
  CrossrefPubMedGoogle Scholar
• 19 Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009; 38 (4) 463-474
  CrossrefPubMedGoogle Scholar
• 20 Westin GG, Armstrong EJ, Bang H , et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63 (7) 682-690
  CrossrefPubMedGoogle Scholar
• 21 Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008; 47 (4) 774-781
  CrossrefPubMedGoogle Scholar
• 22 O'Neil-Callahan K, Katsimaglis G, Tepper MR , et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45 (3) 336-342
  CrossrefPubMedGoogle Scholar
• 23 Poldermans D, Bax JJ, Kertai MD , et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107 (14) 1848-1851
  CrossrefPubMedGoogle Scholar
• 24 Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45 (4) 645-654
  CrossrefPubMedGoogle Scholar
• 25 Ardati AK, Kaufman SR, Aronow HD , et al. The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. Circ Cardiovasc Interv 2012; 5 (6) 850-855
  CrossrefPubMedGoogle Scholar
• 26 Sharma S, Thapa R, Jeevanantham V , et al. Comparison of lipid management in patients with coronary versus peripheral arterial disease. Am J Cardiol 2014; 113 (8) 1320-1325
  CrossrefPubMedGoogle Scholar
• 27 Blum AS. Management of dyslipidemia with statins in the patient with peripheral arterial disease. Tech Vasc Interv Radiol 2006; 9 (2) 50-55
  CrossrefPubMedGoogle Scholar
• 28 National Institute for Health and Care Excellence. Lipid Modification Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease (CG 67). London: National Institute for Health and Care Excellence; 2010
  Google Scholar
• 29 National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events (TA94). London: National Institute for Health and Care Excellence; 2008. Available at: http://www.nice.org.uk/guidance/ta94 . Accessed June 30, 2014
  Google Scholar
• 30 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326) 7-22
  CrossrefPubMedGoogle Scholar
• 31 National Institute for Health and Care Excellence. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial hypercholesterolaemia (TA132). London: National Institute for Health and Care Excellence; 2007
  Google Scholar
• 32 Joosten MM, Pai JK, Bertoia ML , et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012; 308 (16) 1660-1667
  CrossrefPubMedGoogle Scholar
• 33 Rapsomaniki E, Timmis A, George J , et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932) 1899-1911
  CrossrefPubMedGoogle Scholar
• 34 Adler AI, Stratton IM, Neil HA , et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321 (7258) 412-419
  CrossrefPubMedGoogle Scholar
• 35 Williams B, Poulter NR, Brown MJ , et al; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18 (3) 139-185
  CrossrefPubMedGoogle Scholar
• 36 National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults (CG 127). London: National Institute for Health and Care Excellence; 2011. . Available at: http://www.nice.org.uk/guidance/cg127 . Accessed June 30, 2014
  Google Scholar
• 37 Singer DR, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?. Eur J Vasc Endovasc Surg 2008; 35 (6) 701-708
  CrossrefPubMedGoogle Scholar
• 38 Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2013; 12: CD003075
  PubMedGoogle Scholar
• 39 Ostergren J, Sleight P, Dagenais G , et al; HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25 (1) 17-24
  CrossrefPubMedGoogle Scholar
• 40 Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Atherosclerosis 2013; 231 (2) 283-290
  CrossrefPubMedGoogle Scholar
• 41 Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP. Use of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up study. Vasc Endovascular Surg 2012; 46 (7) 515-523
  CrossrefPubMedGoogle Scholar
• 42 Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013; 9: CD005508
  PubMedGoogle Scholar
• 43 American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26 (12) 3333-3341
  CrossrefPubMedGoogle Scholar
• 44 Axelrod DA, Upchurch Jr GR, DeMonner S , et al. Perioperative cardiovascular risk stratification of patients with diabetes who undergo elective major vascular surgery. J Vasc Surg 2002; 35 (5) 894-901
  CrossrefPubMedGoogle Scholar
• 45 Goodney PP, Nolan BW, Schanzer A , et al; Vascular Study Group Of Northern New England. Factors associated with death 1 year after lower extremity bypass in Northern New England. J Vasc Surg 2010; 51 (1) 71-78
  CrossrefPubMedGoogle Scholar
• 46 Abularrage CJ, Conrad MF, Hackney LA , et al. Long-term outcomes of diabetic patients undergoing endovascular infrainguinal interventions. J Vasc Surg 2010; 52 (2) 314-322 , e1–e4
  CrossrefPubMedGoogle Scholar
• 47 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131) 837-853
  CrossrefPubMedGoogle Scholar
• 48 Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig 2014; 5 (2) 134-141
  CrossrefPubMedGoogle Scholar
• 49 Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; 2: CD009122
  PubMedGoogle Scholar
• 50 Hemmingsen B, Lund SS, Gluud C , et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143
  PubMedGoogle Scholar
• 51 Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254 (1) 261-269
  CrossrefPubMedGoogle Scholar
• 52 The Royal College of Radiologists. Standards for Intravascular Contrast Agent Administration to Adult Patients, Second edition. London: The Royal College of Radiologists; 2010
  Google Scholar
• 53 Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88 (6) 787-800
  CrossrefPubMedGoogle Scholar
• 54 Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; (11) CD001272
  PubMedGoogle Scholar
• 55 Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 2012; 21 (4) 187-194
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Committee CS ; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038) 1329-1339
  CrossrefPubMedGoogle Scholar
• 57 Saadeh C, Sfeir J. Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery. J Vasc Surg 2013; 58 (6) 1586-1592
  CrossrefPubMedGoogle Scholar
• 58 Greenhalgh J, Bagust A, Boland A , et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess 2011; 15 (31) 1-178
  PubMedGoogle Scholar
• 59 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637) 195-198
  CrossrefPubMedGoogle Scholar
• 60 Laine M, Arméro S, Peyrol M , et al. Clinical impact of genetically determined platelet reactivity. J Cardiovasc Transl Res 2013; 6 (3) 398-403
  CrossrefPubMedGoogle Scholar
• 61 Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM. Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurol Scand 2013; 128 (4) 213-219
  CrossrefPubMedGoogle Scholar
• 62 Kastrati A. New anti-platelet agents: the end of resistance?. Thromb Res 2012; 130 (Suppl. 01) S53-S55
  CrossrefPubMedGoogle Scholar
• 63 Cattaneo M. The role of laboratory monitoring in antiplatelet therapy. Handbook Exp Pharmacol 2012; (210) 471-494
  PubMedGoogle Scholar
• 64 Janssen PW, ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013; 6 (3) 316-328
  CrossrefPubMedGoogle Scholar
• 65 Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012; 8: CD002071
  PubMedGoogle Scholar
• 66 Alonso-Coello P, Bellmunt S, McGorrian C , et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl) e669S-690S
  CrossrefPubMedGoogle Scholar
• 67 Allemang MT, Rajani RR, Nelson PR, Hingorani A, Kashyap VS. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg 2013; 27 (1) 62-67
  CrossrefPubMedGoogle Scholar
• 68 Lee CW, Ahn JM, Park DW , et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3) 304-312
  CrossrefPubMedGoogle Scholar
• 69 Park SJ, Park DW, Kim YH , et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15) 1374-1382
  CrossrefPubMedGoogle Scholar
• 70 Matas M, Domínguez González JM, Montull E. Antiplatelet therapy in endovascular surgery: the RENDOVASC study. Ann Vasc Surg 2013; 27 (2) 168-177
  CrossrefPubMedGoogle Scholar
• 71 Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996; 8 (4) 299-322
  CrossrefPubMedGoogle Scholar
• 72 de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2012; 12: CD001368
  PubMedGoogle Scholar
• 73 Squires H, Simpson E, Meng Y , et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2011; 15 (40) 1-210
  PubMedGoogle Scholar
• 74 Meng Y, Squires H, Stevens JW , et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology 2014; 65 (3) 190-197
  CrossrefPubMedGoogle Scholar
• 75 Stevens JW, Simpson E, Harnan S , et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012; 99 (12) 1630-1638
  CrossrefPubMedGoogle Scholar
• 76 National institute for Health and Care Excellence. Cilostazol, Naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223). Available at: http://www.nice.org.uk/guidance/ta223 . Accessed June 30, 2014
  PubMedGoogle Scholar
• 77 Smith FB, Bradbury A, Fowkes G. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev 2012; 7: CD002070
  PubMedGoogle Scholar
• 78 Pearce L, Ghosh J, Counsell A, Serracino-Inglott F. Cilostazol and peripheral arterial disease. Expert Opin Pharmacother 2008; 9 (15) 2683-2690
  CrossrefPubMedGoogle Scholar
• 79 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; (1) CD003748
  PubMedGoogle Scholar
• 80 de Franciscis S, Gallelli L, Battaglia L , et al. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J 2013; (e-pub ahead of print). doi:10.1111/iwj.12085
  PubMedGoogle Scholar
• 81 Iida O, Yokoi H, Soga Y , et al; STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127 (23) 2307-2315
  CrossrefPubMedGoogle Scholar
• 82 Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48 (1) 144-149
  CrossrefPubMedGoogle Scholar
• 83 Lee SW, Park SW, Kim YH , et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008; 51 (12) 1181-1187
  CrossrefPubMedGoogle Scholar
• 84 Soga Y, Yokoi H, Kawasaki T , et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53 (1) 48-53
  CrossrefPubMedGoogle Scholar
• 85 Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg 2012; 44 (6) 577-581
  CrossrefPubMedGoogle Scholar
• 86 Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012; 1: CD005262
  PubMedGoogle Scholar
• 87 Di Minno MN, Milone M, Russolillo A , et al. Ropivacaine infusion in diabetics subject with peripheral arterial disease. A prospective study. Exp Clin Endocrinol Diabetes 2013; 121 (2) 91-93
  Article in Thieme ConnectPubMedGoogle Scholar
• 88 Aurilio C, Pace MC, Passavanti MB , et al. Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine. Pain Pract 2009; 9 (2) 105-114
  CrossrefPubMedGoogle Scholar
• 89 Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2013; 2: CD004001
  PubMedGoogle Scholar
• 90 McCormick Z, Chang-Chien G, Marshall B, Huang M, Harden RN. Phantom limb pain: a systematic neuroanatomical-based review of pharmacologic treatment. Pain Med 2014; 15 (2) 292-305
  CrossrefPubMedGoogle Scholar
• 91 Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev 2011; (12) CD006380
  PubMedGoogle Scholar
• 92 Ypsilantis E, Tang TY. Pre-emptive analgesia for chronic limb pain after amputation for peripheral vascular disease: a systematic review. Ann Vasc Surg 2010; 24 (8) 1139-1146
  CrossrefPubMedGoogle Scholar
• 93 Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; (1) CD006544
  PubMedGoogle Scholar
• 94 Matsuo H, Shigematsu H. Patient-based outcomes using the Walking Impairment Questionnaire for patients with peripheral arterial occlusive disease treated with Lipo-PGE1. Circ J 2010; 74 (2) 365-370
  CrossrefPubMedGoogle Scholar
• 95 Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013; 4: CD000986
  PubMedGoogle Scholar
• 96 Hirsch AT, Haskal ZJ, Hertzer NR , et al; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113 (11) e463-e654
  CrossrefPubMedGoogle Scholar
• 97 Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene 2013; 525 (2) 220-228
  CrossrefPubMedGoogle Scholar
• 98 Lederman RJ, Mendelsohn FO, Anderson RD , et al; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359 (9323) 2053-2058
  CrossrefPubMedGoogle Scholar
• 99 Shimamura M, Nakagami H, Taniyama Y, Morishita R. Gene therapy for peripheral arterial disease. Expert Opin Biol Ther 2014; 14 (8) 1175-1184
  CrossrefPubMedGoogle Scholar
• 100 Isner JM, Pieczek A, Schainfeld R , et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348 (9024) 370-374
  CrossrefPubMedGoogle Scholar
• 101 Baumgartner I, Pieczek A, Manor O , et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97 (12) 1114-1123
  CrossrefPubMedGoogle Scholar
• 102 Kusumanto YH, van Weel V, Mulder NH , et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17 (6) 683-691
  CrossrefPubMedGoogle Scholar
• 103 Grossman PM, Mendelsohn F, Henry TD , et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007; 153 (5) 874-880
  CrossrefPubMedGoogle Scholar
• 104 Morishita R, Makino H, Aoki M , et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31 (3) 713-720
  CrossrefPubMedGoogle Scholar
• 105 Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012; 99 (1) 6-15
  PubMedGoogle Scholar
• 106 Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013; 42 (5) 331-339
  CrossrefPubMedGoogle Scholar
• 107 Asahara T, Murohara T, Sullivan A , et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275 (5302) 964-967
  CrossrefPubMedGoogle Scholar
• 108 Tateishi-Yuyama E, Matsubara H, Murohara T , et al; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360 (9331) 427-435
  CrossrefPubMedGoogle Scholar
• 109 Iafrati MD, Hallett JW, Geils G , et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 2011; 54 (6) 1650-1658
  CrossrefPubMedGoogle Scholar
• 110 Botham CM, Bennett WL, Cooke JP. Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist Debakey Cardiovasc J 2013; 9 (4) 201-205
  PubMedGoogle Scholar
• 111 Walter DH, Krankenberg H, Balzer JO , et al; PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4 (1) 26-37
  CrossrefPubMedGoogle Scholar
• 112 Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev 2011; (12) CD008347
  PubMedGoogle Scholar